Welcome to our dedicated page for Aurinia Pharmace SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Canadian‑incorporated biopharmaceutical issuer listed in the United States. Aurinia files annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K, along with exhibits such as earnings releases and investor presentations.
Recent Form 8‑K filings referenced in the available data show how Aurinia uses current reports to furnish quarterly financial results, updates on its share repurchase plan and key clinical developments. For example, the company has filed 8‑Ks to furnish earnings releases for quarters ended March 31, June 30 and September 30, 2025, and to report positive Phase 1 results for aritinercept (AUR200), its dual BAFF and APRIL inhibitor. These filings often attach press releases and presentations as exhibits, providing additional context on revenue, net product sales of LUPKYNIS (voclosporin), license and collaboration revenue, and operating expenses.
Through its periodic reports, Aurinia discloses condensed consolidated balance sheets, statements of operations and cash flows, detailing items such as cash, investments, inventory, lease liabilities, deferred revenue and shareholders’ equity. Investors analyzing AUPH can use 10‑K and 10‑Q filings to review the company’s financial position, revenue composition between LUPKYNIS net product sales and collaboration income, and risk factor discussions related to its autoimmune disease focus.
On Stock Titan, these SEC filings are complemented by AI‑powered summaries that highlight the main points of lengthy documents, helping readers quickly identify changes in revenue, profitability, cash flows or capital allocation, such as the expansion of a share repurchase plan. Real‑time updates from EDGAR ensure that new Aurinia 10‑K, 10‑Q, 8‑K and related exhibits, as well as insider transaction reports on Form 4 when filed, are surfaced promptly with simplified explanations for easier review.
Aurinia Pharmaceuticals senior vice president and chief medical officer Greg Keenan reported a routine share withholding tied to equity compensation. On 02/02/2026, 11,552 shares of common stock were withheld at $14.53 per share to satisfy tax obligations when restricted stock units vested.
After this tax-related withholding, Keenan beneficially owns 121,932 shares of Aurinia common stock, held directly. The filing reflects an administrative adjustment rather than an open-market purchase or sale, and confirms his ongoing equity stake in the company.
Aurinia Pharmaceuticals Inc. (AUPH) filed a Form 4 reporting a tax-related share withholding by a director. On 11/21/2025, a director had 2,716 common shares withheld at a price of $15.68 per share to cover tax obligations when restricted stock units vested. This was recorded as a disposition of shares for tax purposes, not an open-market sale. After this transaction, the director beneficially owns 22,775 common shares, held directly.
The filing clarifies that the reported transaction represents shares withheld to satisfy tax withholding obligations upon RSU vesting, which is a common administrative equity compensation event for insiders.
Aurinia Pharmaceuticals Inc. (AUPH) reported an insider equity transaction on a Form 4 involving one director. On 11/21/2025, the director had 6,039 common shares withheld at a price of $15.68 per share to cover tax withholding obligations tied to the vesting of restricted stock units. After this tax-related withholding, the director directly beneficially owned 14,592 common shares of Aurinia. This event reflects routine equity compensation and tax management rather than an open-market purchase or sale.
Aurinia Pharmaceuticals Inc. (AUPH) furnished an 8‑K on November 4, 2025 announcing it issued a press release for its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1, with a Third Quarter 2025 Update as Exhibit 99.2.
The information was furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically stated. The report was signed by Chief Financial Officer Joseph Miller.
Aurinia Pharmaceuticals (AUPH) reported stronger Q3 2025 results, led by continued LUPKYNIS growth and lower operating costs. Total revenue was $73.5 million, up from $67.8 million a year ago, with net product sales of $70.6 million. Net income rose to $31.6 million from $14.4 million as SG&A spending declined following 2024 restructuring actions. Gross margin was 89% for the quarter.
Year to date, revenue reached $205.9 million and net income was $76.4 million. Operating cash flow for the nine months was $90.0 million. Cash, cash equivalents, restricted cash and investments were $351.8 million as of September 30, 2025. The company repurchased 12.2 million common shares year to date under its authorized program. Common shares outstanding were 131,840,559 as of November 3, 2025.
This Amendment No. 16 to the Schedule 13D reports the holdings and recent transactions by ILJIN-related reporting persons in Aurinia Pharmaceuticals Inc.'s common shares. Chin Kyu Huh beneficially owns 6,535,141 shares, equal to 5.0% of the outstanding class, and certain ILJIN entities report shared voting and dispositive power over 5,411,533 shares (4.1%). The filing states small purchases by family members and material secondary-market sales by ILJIN SNT and a family member, with per-share prices disclosed.
The filing also states the Reporting Persons may be deemed a group for Section 13(d)(3) purposes while disclaiming certain beneficial ownerships among family members and entities. All percentage calculations are based on 131,629,546 shares outstanding as reported by the issuer.
Aurinia Pharmaceuticals Inc. (AUPH) – Form 4 insider buying
Director Kevin Tang, through Tang Capital Partners LP and Tang Capital Partners International LP, purchased a total of 1,300,000 common shares in three open-market transactions dated 1-5 Aug 2025 (transaction code P). Weighted-average purchase prices were:
- 1,000,000 sh @ $10.12 (range $9.23-$10.50)
- 100,000 sh @ $11.34 (range $11.11-$11.48)
- 200,000 sh @ $11.68 (range $11.49-$11.80)